tbuckley/cabot-search huggingface dataset:
POS1194-HPR EFFECTS OF RAMADAN INTERMITTENT FASTING ON RHEUMATIC DISEASES
Authors: A. Mougui, H. Tebaa, I. El Bouchti
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Intermittent fasting (IF) during the month of Ramadan is one of the 5 fundamental pillars of Islam. Many patients report that IF improves or worsens their symptoms during this month, however, few studies had assessed the impact of IF on rheumatic diseases. <h3>Objectives</h3> The present study was conducted to assess the impact of IF during the month of Ramadan on rheumatoid arthritis (RA) and spondyloarthritis (SpA) activity. <h3>Methods</h3> The study included 71 patients with RA or SpA who fasted during Ramadan of 2022. Patients were assessed in 2 visits: 4 months before the month of Ramadan and the second after fasting at least after 15 days. <h3>Results</h3> RA group: 49 patients were included. IF was associated with a significant decrease in VAS (Visual analogue Scale) pain (5.76± 2.16 to 3.14 ±1.47) (p &lt; 0.001), duration of morning stiffness (47,76 ± 39,68 minutes to 11,73 ± 11,11 minutes) (p &lt; 0,001), number of painful joints (13,35 ± 5,43 to 7,36 ± 0,71) (p&lt;0.001), number of synovitis(12,84 ± 6,715 to 3,04 ± 3,6) (p&lt;0.001), CDAI (18.29 ± 4.74 to 12.35 ± 3.48) (p&lt;0.001), SDAI (20.39 ±4.86 to 10.32± 4.68) (p &lt; 0.001), DAS28 ESR (4.003 ± 0.1 to 2.55 ± 1.39) (p &lt; 0.001), and DAS 28 CRP (4.06 ± 0.89 to 2.15 ± 0.77) (p &lt; 0.001). SpA group: 22 were included. IF was associated with a significant decrease in VAS pain (5,14 ± 1,93 to 3,05 ± 1,70) (p &lt; 0.001), number of painful joints (10,91 ± 5,63 to 1,27 ± 4,24) (p&lt;0.001), number of synovitis (12,41± 6,71 to 1,73± 1,38) (p&lt;0.001), BASDAI (4.92 ± 0.88 to 2.28 ± 0.81) (p&lt;0.001), ASDAS CRP (4.44 ± 0.69 to 2.49 ± 1.29) (p&lt; 0.001), and ASDAS ESR (4.12± 0.83 to 2.55± 1.39) (p&lt;0.001). <h3>Conclusion</h3> IF was associated with significant improvement in RA and SPA activity. It is a promising non-pharmacological therapeutic option for patients with RA and SpA. Larger sample studies with control groups are needed to confirm these findings. <h3>References</h3> [1] Ben Nessib D, Maatallah K, Ferjani H, Triki W, Kaffel D, Hamdi W. Sustainable positive effects of Ramadan intermittent fasting in rheumatoid arthritis. Clin Rheumatol. 2022 Feb;41(2):399-403 [2] Siddique S, Imran Y, Afzal MN, Malik U. Effect of Ramadan fasting on disease activity in patients with rheumatoid arthritis presenting in tertiary care hospital. Pak J Med Sci. 2020 Jul-Aug;36(5):1032-1035. [3] Ben Nessib D, Maatallah K, Ferjani H, Kaffel D, Hamdi W. The potential effect of Ramadan fasting on musculoskeletal diseases: new perspectives. Clin Rheumatol. 2021 Mar;40(3):833-839. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB0966 EFFICACY AND SAFETY OF SECUKINUMAB IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: SINGLE CENTER EXPERIENCE
Authors: F. Taş, S. Gulle, F. Onen, İ. Sari
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Secukinumab (SCK), the first-in-class human monoclonal antibody against interleukin-17A, has been approved for the treatment of AS in many countries, including the US and EU. The efficacy of subcutaneous secukinumab in the treatment of Ax-SpA was primarily evaluated in five multicenter, phase III studies that included four randomized double-blind studies (MEASURE Studies). However, there are few studies evaluating long-term SCK efficacy in real-life data in patients with AxSpA [1,2]. <h3>Objectives</h3> Our aim in this study is to retrospectively evaluate the clinical findings and treatment response status of patients who were followed up with the diagnosis of Ax-SpA and using SCK. <h3>Methods</h3> A total of 60 patients who were followed up with the diagnosis of akSpA in our rheumatology clinic were included in the study. Demographic characteristics of the patients, comorbidities, duration of symptoms, delay in diagnosis, biologics and DMARDS were recorded. In the evaluation of the patients, BASDAI, BASFI, ASDAS, VAS pain, and VAS global scores were recorded as baseline, 3, 6, 12 and 24th months. The number and order of treatment before SEC in patients using bDMARDs were also examined, and SCK efficacy and drug retention characteristics were investigated between the biological treatment naive and resistant groups. Variables were analyzed at 95% confidence level, and p value less than 0.05 was considered significant. <h3>Results</h3> Follow-up data of 60 patients diagnosed with SpA (n=50 AS and n=10 nr-AxSpA) followed in a single center (inception cohort) were evaluated. Of these patients, 15 (25%) were bDMARD naive patients and 45 (75%) had used ≥1 bDMARD before SEC. The age and gender distribution was similar between the bDMARD naive and ≥1 bDMARD group. At 1-year follow-up, 1 and 7 patients discontinued their treatment in the ≥1 bDMARD group and the SCK group, respectively (p&lt;0.001) (Table 1). The retention rate at 24 months was 80% and 49% in the naive and ≥1 bDMARD patients, respectively (p=0.026) (Figure 1). In our study, no significant drug-related serious adverse events or safety problems were encountered in the follow-up of secukinumab treatment for more than 36 months. <h3>Conclusion</h3> We found that SCK treatment in patients with Ax-SpA had better clinical response and higher drug survival rates in biologic naive patients, similar to TNFi treatment in real-life data. However, better drug retention rates were found in naive patients compared to patients using &gt;1 bdmard, which is consistent with the results of previous studies. <h3>References</h3> [1]Williams T, et al. Clin Rheumatol. 2020 May 27;39(5):1501–4. [2]Ward MM, Deodhar A, et al. Arthritis Care Res (Hoboken). 2019;71(10):1285–99. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
Cardiotoxicity of BRAF/MEK Inhibitors
Authors: Claire Glen, Sarah Adam, Kirsty McDowell, Ashita Waterston, Yun Yi Tan, Mark C. Petrie, Caroline J. Coats, Ninian N. Lang
Journal: JACC CardioOncology (2023)

Rapidly accelerated fibrosarcoma B-type (BRAF) and mitogen-activated extracellular signal-regulated kinase (MEK) inhibitors have revolutionized treatment for patients with BRAF-mutated melanoma. Although left ventricular systolic dysfunction associated with these therapies has been reported in clinical trials, the real-world incidence is poorly defined, as are risk factors for its development.This study sought to characterize the incidence, time course, and risk factors for cancer therapy-related cardiac dysfunction (CTRCD) in patients with melanoma receiving BRAF and MEK inhibitors.Patients with melanoma treated with BRAF and MEK inhibitors at a cancer hospital network between June 1, 2017, and June 30, 2020, were included retrospectively. CTRCD was defined as mild, moderate, or severe according to International Cardio-Oncology Society (ICOS) definitions. Baseline cardiotoxicity risk stratification was performed using the Heart Failure Association/ICOS tool.Of the 63 patients included, 27% developed CTRCD (17% mild and 10% moderate). No patients developed severe CTRCD or symptomatic heart failure. CTRCD occurred most frequently in patients considered to be at "low" and "medium" baseline risk of cardiotoxicity (82%). The baseline left ventricular ejection fraction and global longitudinal strain were not different in patients who developed moderate CTRCD vs those who did not. Left ventricular internal diameters in diastole and systole were larger in patients who developed moderate CTRCD compared with those who did not (left ventricular internal diameter in diastole: 4.9 ± 0.6 cm vs 4.3 ± 0.6 cm; P = 0.023; left ventricular internal diameter in systole: 3.3 ± 0.4 cm vs 2.8 ± 0.5 cm; P = 0.039).BRAF and MEK inhibitor-associated CTRCD is common. The utility of the Heart Failure Association/ICOS risk stratification tool appears limited in this group, and better risk prediction tools are needed. The long-term consequences of CTRCD, particularly mild CTRCD, warrant evaluation in larger prospective studies.
AB1642 A NATIONWIDE POPULATION-BASED STUDY OF EPIDEMIOLOGY, RISK FACTORS FOR CYTOMEGALOVIRUS DISEASE IN AUTOIMMUNE INFLAMMATORY RHEUMATIC DISEASES
Authors: T. H. LI, Y. S. Chang, C. F. Su, C. C. Lai, C. C. Chuang, C. Y. Tsai
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Human cytomegalovirus (CMV) ubiquitously distributes in general population but may cause overwhelming complications in patients with autoimmune inflammatory rheumatic diseases (AIIRDs); hence, the prevalence and associated factors of CMV disease in AIIRDs is worth investigating but the data has been limited. <h3>Objectives</h3> To investigate the epidemiologic data and risk factors of CMV infection in patients with AIIRDs. <h3>Methods</h3> The nationwide population-based cohort study was conducted by using Taiwanese National Health Insurance Database, to compare incidence rates (IR) with incidence rate ratios (IRR) of CMV disease in patients with AIIRDs and non-AIIRDs age- and sex-matched cohort; CMV disease was defined as pertinent ICD codes with concurrent anti-CMV medication administration. The individual data in various AIIRDs were analyzed and risk factors were identified by Cox proportional regression. <h3>Results</h3> 94,429 patients with AIIRDs and 1:1 number of matched subjects were identified; higher incidence rate of CMV disease in AIIRDs group was noted than the matched cohort. Various comorbidities and therapeutic agents including azathioprine, cyclosporin, cyclophosphamide, mycophenolate, intravenous steroid and oral daily dose &gt; 7.5mg prednisolone or equivalence, were associated with CMV disease incidence. Comparing with RA, SLE and DM/PM posed increased risks on CMV disease. <h3>Conclusion</h3> Patients with AIIRDs carry higher risk of CMV disease regardless of etiologies, and attentiveness to one's health is indispensable to facilitate early detection of CMV disease in patients with AIIRDs. <h3>References</h3> [1]Zuhair M, Smit GSA, Wallis G <i>et al.</i> Estimation of the worldwide seroprevalence of cytomegalovirus: A systematic review and meta-analysis. <i>Rev Med Virol.</i> 2019;29:e2034. [2]Choo HMC, Cher WQ, Kwan YH <i>et al.</i> Risk factors for cytomegalovirus disease in systemic lupus erythematosus (SLE): a systematic review. <i>Adv Rheumatol.</i> 2019;59:12. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB1034 COSTOVERTEBRAL JOINTS INVOLVEMENT IN RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: A CASE-SERIES COMPUTED TOMOGRAPHY STUDY
Authors: A. Shouval, S. Croitoru, S. Keret, I. Eshed, G. Slobodin
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> The involvement of the costovertebral joints (CVJ) and its radiographic patterns in patients with radiographic axial spondyloarthritis (rAxSpA) and thoracic pain were described more than three decades ago, however the extent and details of structural damage in the CVJ have never been assessed. <h3>Objectives</h3> To evaluate structural changes of CVJ in patients with rAxSpA using available computed tomography (CT) studies. <h3>Methods</h3> Available chest or thoracic spine CT studies of 17 patients with rAxSpA and 17 patients with rheumatoid arthritis (RA) were analyzed. Ankylosis, erosions, joint space narrowing and osteophytes of both components of the CVJ, including head-vertebral joints (HVJ) and costotransverse joints (CTJ), were noted and compared between patient groups. The distribution of the structural changes of the CVJ along the thoracic spine was assessed. <h3>Results</h3> The groups were similar by patients' average age, but the rAxSpA group included more males (11/17) compared to the RA group (4/17, p=0.036). In all, 748 CVJ were assessed in each patient group, including 408 head-vertebral joints (HVJ) and 340 costotransverse joints (CTJ). rAxSpA patients had significantly more total CVJ lesions (p&lt;0.001 for all comparisons), more lesions in the HVJ (p&lt;0.001, for all comparisons), and more lesions in the CTJ (p≤0.005, for all comparisons, except for osteophytes), compared to RA group. All types of lesions, including ankylosis, erosions, narrowing, and osteophytes, were seen more frequently in rAxSpA patients. Joint space narrowing and ankylosis of the CVJ were the most frequently seen findings in rAxSpA and were distributed throughout the thoracic spine. <h3>Conclusion</h3> Structural pathology of the CVJ was more commonly observed in patients with rAxSpA than in RA patients in this study. <h3>Reference</h3> [1]Pascual E, Castellano JA, López E (1992) Costovertebral joint changes in ankylosing spondylitis with thoracic pain. Br J Rheumatol. Jun;31(6):413-5. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB0995 ASSESSMENT OF MATRIX METALLOPROTEINASE-3 IN SPONDYLOARTHRITIS: CORRELATION WITH DISEASE ACTIVITY
Authors: M. Slouma, S. Bouzid, L. Kharrat, A. Tezeghdenti, E. Ghazouani, L. Metoui, R. Dhahri, I. Gharsallah, B. Louzir
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Several studies showed that the activity of proteinases, including matrix metalloproteinases (MMPs), is increased in inflamed tissue, via the overproduction of pro-inflammatory cytokines, in spondyloarthritis (SpA) [1]. <h3>Objectives</h3> Our study aimed to assess the correlation between serum levels of MMP-3 and disease activity in SpA. <h3>Methods</h3> We conducted a cross-sectional study including patients with SpA, diagnosed according to ASAS 2009 criteria. ELISA technique was used to measure MMP-3 serum levels. CRP and ESR were also measured. Disease activity was assessed with Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Ankylosing Spondylitis Disease Activity Score (ASDAS-CRP). Pearson correlation coefficient was calculated. <h3>Results</h3> We included 82 patients. The mean age was 45.32 ± 13.41 years [20-80]. Male to female ratio was 3.82. The mean disease duration was 7.57 ± 7.79 years. Radiographic axial SpA (r-AxSpA) and psoriatic arthritis (PsA) were noted in 65.9% (n=54) and 34.1% (n=28) of cases, respectively. The mean MMP-3 serum levels were 64.14 + 187.31 ng/mL [1.75 – 1237.36]. The mean CRP and ESR levels were 20.64 + 24.52 mg/l and 35.46 + 31.69 mm, respectively. The mean BASDAI and ASDAS-CRP were 3.26 ± 1.89 and 2.98 ± 1.45, respectively. MMP-3 serum levels correlated significantly with inflammatory biomarkers: CRP (r=0.314, <b>p=0.004</b>) and ESR (r=0.291, <b>p=0.013</b>). A correlation was also found with ASDAS-CRP (r=0.245, <b>p=0.028</b>). However, no correlation was found between MMP-3 serum levels and BASDAI (r=0.204, p=0.070). <h3>Conclusion</h3> Our results showed that MMP-3 serum levels correlate significantly with inflammatory biomarkers (CRP and ESR) and with ASDAS-CRP. MMP-3 seems to be a promising biomarker for disease activity in SpA. <h3>Reference</h3> [1]Gao JW, Zhang KF, Lu JS, Su T. Serum matrix metalloproteinases-3 levels in patients with ankylosing spondylitis. Genet Mol Res. 2015;14(4):17068‑78. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
POS1048 SEMAPHORIN3B PROMOTES A RESOLVING-INFLAMMATION PHENOTYPE IN MACROPHAGES FROM RHEUMATOID ARTHRITIS PATIENTS
Authors: S. Martínez-Ramos, C. Rafael Vidal, B. Malvar Fernández, N. Perez-Gomez, C. Mouriño Rodríguez, F. J. Maceiras-Pan, I. Altabás González, J. M. Pego-Reigosa, S. García
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Our group have recently shown that (Sema)phorin3B is reduced in RA patients and plays a protective role in an arthritis mouse model, through the reduction of inflammatory mediators and the synovial fibroblast invasiveness and was associated with a reduction of CD68 positive synovial macrophages (Igea, 2022). On the other hand, MerTK is a receptor protein kinase involved in the resolution of inflammation and plays a protective role in arthritis mice models (Waterborg, 2018). A recent study has shown that a population of synovial tissue macrophages characterized by the expression of MerTK are associated with remission maintenance and with an anti-inflammatory phenotype of RA FLS (Alivernini, 2020). <h3>Objectives</h3> The aim of this study is to determine the role of Sema3B in the phenotypic characteristics of RA macrophages and the implication of MerTK. <h3>Methods</h3> Peripheral blood monocytes from RA patients (n=10) were differentiated into macrophages by culturing in the presence of IFN-γ (10 ng/mL) for 6 days. Afterwards, macrophages were stimulated for 24 h with LPS (10 ng/mL), Sema3B (200 ng/mL) or the combination of both mediators. The expression of pro- and anti-inflammatory mediators was determined by quantitative PCR (qPCR) and ELISA. The expression of MerTK and macrophage surface markers was measured by flow cytometry. <h3>Results</h3> Sema3B did not modulate the macrophage expression of pro-inflammatory mediators <i>IL1B, IL6, IL12B, IL23, TNF, CCL2, CXCL10</i> and <i>CD86</i>, but significantly reduced the LPS-induced expression of these mediators (Figure 1A), as well as the protein secretion of IL6, IL12p70 and TNF. In addition, Sema3B alone, but not in combination with LPS, significantly induced the gene and protein expression of MerTK and the secretion of Resolvin D1, a MerTK-mediated lipid involved in resolution of inflammation (Figure 1B). Moreover, Sema3B reduced the expression of the M1 marker CD64, while induced the expression of the M2 marker CD163. <h3>Conclusion</h3> Our data demonstrate that Sema3B modulates the macrophage phenotype of RA macrophages, inducing a skewing towards an anti-inflammatory/pro-resolving phenotype, likely in a MerTK-dependent manner. Therefore, here we identified a new mechanism involved in the protective role of Sema3B in RA pathogenesis. <h3>References</h3> [1] Alivernini, S. <i>et al. Nat. Med.</i><b>26</b>, 1295–1306 (2020). [2] Igea, A. <i>et al. Arthritis Rheumatol.</i><b>74(6</b>), 972–983(2022). [3] Waterborg CEJ, et al. <i>Front. Immunol</i>. 9:742 (2018). <h3>Acknowledgements</h3> All patients involved in this study. <h3>Disclosure of Interests</h3> None Declared.
AB0561 RITUXIMAB EFFICACY IN LUPUS NEPHRITIS: SYSTEMATIC REVIEW OF THE LITERATURE AND META-ANALYSIS
Authors: R. Dos-Santos, C. Deus, D. Fernández Fernández, I. González Fernández, M. Sanchez-Wonenburger, P. Castro-Santamaria, J. L. Puga Guzmán, A. Mata, I. Álvarez, V. Busto, J. R. Maneiro, A. Souto Vilas, A. Mera Varela, E. Perez-Pampín
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Lupus nephritis (LN) is one of the most harmful clinical manifestation in systemic lupus erythematosus (SLE) patients. Despite of the existence of standard treatment protocols, a percentage of patients cannot be controlled with classical immunosuppresant drugs. This is the reason for exploring new therapies, such rituximab (RTX), in order to achieve a better management of LN <sup>[1,2]</sup>. <h3>Objectives</h3> To assess the efficacy of RTX in LN treatment. <h3>Methods</h3> A systematic review was performed using Medline, Embase, Cochrane Library and Web of Science databases. Two independent reviewers selected the records that fitted the inclusion and exclusion criteria. Statistical analysis was carried out with Stata 15.1 for MacOS (StataCorp). Relating to meta-analysis, odds ratio (OR) was chose as measure of association in registries with control group and a prevalence meta-analysis was conducted in those registries without it. <h3>Results</h3> 436 papers were obtained from the search, finally 32 articles were analysed. Meta-analysis of registries with control group showed a significant higher rate of total response in LN patients treated with RTX, compared to control group (OR 2.154, 95%CI 1.271-3.650, p=0.004) after 52 weeks of follow-up (Figure 1). As well, a non-significant higher rate of complete response in LN patients treated with RTX, compared to control group (p=0.062) was found after 52 weeks of follow-up. A non-significant lower rate of partial response in LN patients treated with RTX compared to control group was found. Prevalence meta-analysis of registries without control group showed response in more than 50% of LN patients treated with RTX. <h3>Conclusion</h3> RTX seems to be effective in long-term treatment LN patients (52 weeks). More clinical trials are needed for clear indication of RTX for SLE treatment and its inclusion in general clinical practice. <h3>References</h3> [1]Kaul, A., Gordon, C., Crow, M. et al. Systemic lupus erythematosus. Nat Rev Dis Primers 2, 16039 (2016). [2]Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis &amp; Rheumatology. 2019;71(9):1400-1412. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB1217 COMORBIDITIES DURING GONARTHROSIS
Authors: A. Rafi, S. Belouaham, Z. Baba, A. Mougui, I. El Bouchti
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Osteoarthritis of the knee, together with that of the hip, is the most serious disease of osteoarthritis. Long considered a benign disease, gonarthrosis is nevertheless associated with significant morbidity. <h3>Objectives</h3> To assess the prevalence of co-morbidities in gonarthrosis patients and to assess their impact on pain, functional impact and radiographic progression. <h3>Methods</h3> Our study involved patients with gonarthrosis. Comprehensive comorbidity screening was done. Pain intensity was assessed by the Analogue Visual Scale (EVA). The neuropathic component was assessed by the DN4 score. Functional impact was assessed by the Lequesne index and Womac score. Knee X-rays were classified according to Kellgren Lawrence (KL) criteria. <h3>Results</h3> A total of 215 patients were included (24 men/191 women). The average age was 58.02 ±9.11 years. The mean body mass index was 24.87± 5.39 kg/m2. The main comorbidities were: The visual analogic scale was 7.86± 1.31 and stress at 13.74 ±4.95. The average Womac score was 12.3 ±8.92. The average Lequesne score was 6.71 ±3.20. The average DN4 score was 18.81± 8.9. Comorbidities were associated with age (p = 0.02), DN4 score (p = 0.01), and KL radiographic grades (p = 0.02). <h3>Conclusion</h3> In this study, co-morbidity in gonarthrosis was associated with advanced age, a neuropathic component of pain, and severe structural impairment. <h3>Reference</h3> [1]Comorbidities and osteoarthritis Christian-Hubert Roux, Service de rhumatologie, université Côte d'Azur, LAMHESS, EA 6312, CHU Nice, France,IBV CNRS UMR7277 Inserm, U1091, 06000 Nice, France, revue du rhumatisme 2021 <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.